HEALTH STATE UTILITIES FOR METASTATIC BREAST CANCER IN TAIWAN

•This study obtained health state utility values for metastatic breast cancer (MBC) and grade 3/4 adverse drug reactions (ADRs) using both the time trade-off (TTO) and the visual analogue scale (VAS), which provides useful data for future cost-utility analyses.•Among the MBC health states assessed, the TTO preference score ranged from 0.04 (palliative MBC) to 0.62 (responding MBC).•For grade 3/4 ADRs, the mean TTO-derived utility values ranged from 0.35 (nausea/vomiting) to 0.79 (fatigue).